Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at Morgan Stanley

Morgan Stanley initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $70.00 price objective on the stock.

A number of other brokerages also recently commented on KYMR. Guggenheim reaffirmed a “buy” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. UBS Group lowered their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Jefferies Financial Group set a $64.00 price objective on shares of Kymera Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 25th. B. Riley raised shares of Kymera Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $38.00 to $60.00 in a research report on Tuesday, June 3rd. Finally, Wells Fargo & Company lowered their price objective on shares of Kymera Therapeutics from $57.00 to $53.00 and set an “overweight” rating on the stock in a research report on Thursday, June 26th. Two research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $59.11.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $44.81 on Thursday. The firm’s 50 day simple moving average is $38.46 and its 200-day simple moving average is $35.90. The company has a market cap of $2.92 billion, a P/E ratio of -14.45 and a beta of 2.18. Kymera Therapeutics has a fifty-two week low of $19.45 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 409.07% and a negative return on equity of 30.11%. The firm had revenue of $22.10 million for the quarter, compared to the consensus estimate of $11.38 million. During the same period in the previous year, the firm posted ($0.69) earnings per share. The firm’s revenue was up 114.6% on a year-over-year basis. On average, analysts expect that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the completion of the sale, the chief executive officer directly owned 660,482 shares of the company’s stock, valued at approximately $32,363,618. This represents a 4.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker bought 655,500 shares of the business’s stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average price of $44.00 per share, with a total value of $28,842,000.00. Following the completion of the purchase, the director owned 6,117,295 shares in the company, valued at approximately $269,160,980. The trade was a 12.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 48,349 shares of company stock worth $2,334,301 in the last quarter. 16.01% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of KYMR. State of Wyoming bought a new stake in Kymera Therapeutics in the 4th quarter valued at $45,000. GF Fund Management CO. LTD. bought a new stake in Kymera Therapeutics in the 4th quarter valued at $55,000. KBC Group NV boosted its holdings in Kymera Therapeutics by 15.2% in the 1st quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after purchasing an additional 328 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics in the 1st quarter valued at $68,000. Finally, Advisors Asset Management Inc. boosted its holdings in Kymera Therapeutics by 81.7% in the 1st quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company’s stock valued at $136,000 after purchasing an additional 2,230 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.